Fasiglifam，TAK-875

Nomen chemicum:

(S)-2-(6-(2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3 -dihydrobenzofuran-3-yl) acidum aceticum

SMILES Code:

O=C(O)C[C@@H]1COC2=CC(OCC3=CC(C4=C(C)C=C(OCCCS(=O)(C)=O)C=C4C)=CC=C3 )=CC=C12

InChi Code:

InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21( 14-22) 17-35-24-8-9-26-23 (15-28(30)31) 18-36-27(26)16-24/h4,6-9,12-14,16; 23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1

InChi Key:

BZCALJIHZVNMGJ-HSZRJFAPSA-N

Keyword:

1000413-72-8；CAS:1000413-72-8； CAS： 1000413-72-8；TAK875；TAK-875；TAK 875；Fasiglifam

Solubilitas:Solutum in DMSO, non in aqua

Repono:0 - 4 C ad terminum brevem (dies ad septimanas), vel -20 C ad terminum longi (menses).

Descriptio:

Fasiglifam (TAK-875) est efficax, oralis, et selectiva GPR40 agonist.

Target: GPR40 agonist